The GPR55 antagonist CID16020046 protects against intestinal inflammation

G protein‐coupled receptor 55 (GPR55) is a lysophospholipid receptor responsive to certain cannabinoids. The role of GPR55 in inflammatory processes of the gut is largely unknown. Using the recently characterized GPR55 inhibitor CID16020046, we determined the role of GPR55 in experimental intestinal inflammation and explored possible mechanisms of action.

[1]  M. De Bardi,et al.  The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. , 2015, International immunology.

[2]  B. Rinner,et al.  Synergistic effects of NOD1 or NOD2 and TLR4 activation on mouse sickness behavior in relation to immune and brain activity markers , 2015, Brain, Behavior, and Immunity.

[3]  R. Capasso,et al.  Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti‐inflammatory agent , 2015, British journal of pharmacology.

[4]  R. Franco,et al.  Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling , 2014, British journal of pharmacology.

[5]  Lijun Yao,et al.  Anthocyanin-rich fractions from red raspberries attenuate inflammation in both RAW264.7 macrophages and a mouse model of colitis , 2014, Scientific Reports.

[6]  N. Garrido-Mesa,et al.  Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis. , 2014, Journal of Crohn's & colitis.

[7]  W. Petritsch,et al.  Opposing Roles of Prostaglandin D2 Receptors in Ulcerative Colitis , 2014, The Journal of Immunology.

[8]  A. Irving,et al.  Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling* , 2014, The Journal of Biological Chemistry.

[9]  I. Dotan,et al.  Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[10]  K. Mackie,et al.  A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice , 2013, Neuropharmacology.

[11]  M. Waldhoer,et al.  A Selective Antagonist Reveals a Potential Role of G Protein–Coupled Receptor 55 in Platelet and Endothelial Cell Function , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[12]  K. Mackie,et al.  GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination , 2013, PloS one.

[13]  M. Storr,et al.  A potential role for GPR55 in gastrointestinal functions , 2012, Current opinion in pharmacology.

[14]  M. Waldhoer,et al.  The Cannabinoid Receptor CB1 Modulates the Signaling Properties of the Lysophosphatidylinositol Receptor GPR55* , 2012, The Journal of Biological Chemistry.

[15]  A. Lichtman,et al.  Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice , 2012, Pharmacology.

[16]  S. Popoff,et al.  The Endocannabinoids Anandamide and Virodhamine Modulate the Activity of the Candidate Cannabinoid Receptor GPR55 , 2012, Journal of Neuroimmune Pharmacology.

[17]  M. Storr,et al.  Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice , 2012, Pharmacology.

[18]  R. Price,et al.  Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. , 2012, Toxicology and applied pharmacology.

[19]  E. Kostenis,et al.  GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils , 2011, Cell Research.

[20]  A. Irving,et al.  Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. , 2011, Molecular endocrinology.

[21]  M. Storr,et al.  A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[22]  K. Mackie,et al.  The atypical cannabinoid O‐1602 protects against experimental colitis and inhibits neutrophil recruitment , 2011, Inflammatory bowel diseases.

[23]  M. Caron,et al.  Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. , 2011, Biochemistry.

[24]  T. Montine,et al.  Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity. , 2011, Neurotoxicology.

[25]  Y. Urade,et al.  Increased expression of lipocalin-type-prostaglandin D synthase in ulcerative colitis and exacerbating role in murine colitis. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[26]  G. Velasco,et al.  The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK , 2011, Oncogene.

[27]  A. Irving,et al.  GPR55 ligands promote receptor coupling to multiple signalling pathways , 2010, British journal of pharmacology.

[28]  A. Izzo,et al.  Cannabinoids and the gut: new developments and emerging concepts. , 2010, Pharmacology & therapeutics.

[29]  L. Eckmann,et al.  STAT3 and its activators in intestinal defense and mucosal homeostasis , 2010, Current opinion in gastroenterology.

[30]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[31]  P. Alex,et al.  Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS‐Induced Colitis , 2009, Inflammatory bowel diseases.

[32]  R. Ross.  The enigmatic pharmacology of GPR55. , 2009, Trends in pharmacological sciences.

[33]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[34]  A. Irving,et al.  The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  A. Yamashita,et al.  2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. , 2008, Journal of biochemistry.

[36]  I. Chessell,et al.  The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain , 2008, PAIN.

[37]  Hong Zhang,et al.  Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors , 2008, Journal of Molecular Medicine.

[38]  K. Mackie,et al.  GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current , 2008, Proceedings of the National Academy of Sciences.

[39]  S. Hjorth,et al.  The orphan receptor GPR55 is a novel cannabinoid receptor , 2007, British journal of pharmacology.

[40]  S. Miszputen,et al.  Immunoexpression of cyclooxygenase-1 and -2 in ulcerative colitis. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[41]  Toshio Hirano,et al.  IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. , 2007, International immunology.

[42]  I. Villegas,et al.  The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice , 2005, Inflammation Research.

[43]  R. Kiesslich,et al.  Activation Pattern of Signal Transducers and Activators of Transcription (STAT) Factors in Inflammatory Bowel Diseases , 2005, The American Journal of Gastroenterology.

[44]  M. D'Andrea,et al.  Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium‐induced colitis in mice , 2004, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[45]  C. S. Patil,et al.  Aggravation of Inflammatory Bowel Disease by Cyclooxygenase-2 Inhibitors in Rats , 2004, Pharmacology.

[46]  James J. Lee,et al.  Immunopathogenesis of Experimental Ulcerative Colitis Is Mediated by Eosinophil Peroxidase1 , 2004, The Journal of Immunology.

[47]  B. Cravatt,et al.  The endogenous cannabinoid system protects against colonic inflammation. , 2004, The Journal of clinical investigation.

[48]  I. Villegas,et al.  The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. , 2003, European journal of pharmacology.

[49]  I. Fuss,et al.  Induction of TNBS colitis in mice. , 2002, Current protocols in immunology.

[50]  A. Husband,et al.  The inflammatory infiltrate in the acute stage of the dextran sulphate sodium induced colitis: B cell response differs depending on the percentage of DSS used to induce it , 2001, BMC clinical pathology.

[51]  J. Hunter,et al.  Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease , 2001, Gut.

[52]  W. Falk,et al.  Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. , 2000, European cytokine network.

[53]  S. Kitajima,et al.  Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. , 1999, Experimental animals.

[54]  A. T. Te Velde,et al.  Altered Expression of Interferon‐&ggr; and Interleukin‐4 in Inflammatory Bowel Disease , 1998, Inflammatory bowel diseases.

[55]  G. Rogler,et al.  Alterations of the phenotype of colonic macrophages in inflammatory bowel disease , 1997, European journal of gastroenterology & hepatology.

[56]  K. Vaddi,et al.  Regulation of monocyte integrin expression by beta-family chemokines. , 1994, Journal of immunology.

[57]  W. Falk,et al.  Chemotaxis by mouse macrophage cell lines. , 1981, Journal of immunology.

[58]  Jennifer L. Bath,et al.  the potential role of , 2017 .

[59]  M. Storr,et al.  A potential role for GPR 55 in ga strointestinal functions , 2012 .

[60]  E. Kostenis,et al.  GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils , 2011, Cell Research.